Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kyoungmin | - |
dc.contributor.author | Choi, Yoon J. | - |
dc.contributor.author | Kim, Jung S. | - |
dc.contributor.author | Kim, Dae S. | - |
dc.contributor.author | Lee, Sung Y. | - |
dc.contributor.author | Shin, Bong K. | - |
dc.contributor.author | Kang, Eun J. | - |
dc.date.accessioned | 2022-02-26T02:41:07Z | - |
dc.date.available | 2022-02-26T02:41:07Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 1759-7706 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136943 | - |
dc.description.abstract | Background Brain metastases frequently occur in patients with non-small cell lung cancer (NSCLC) resulting in a poor prognosis. Here, we investigated the association between PD-L1 expression and brain metastasis in patients with NSCLC and its clinical significance. Methods A total of 270 patients diagnosed with metastatic NSCLC who underwent PD-L1 testing on their tumor tissue between January 2017 and March 2019 were retrospectively reviewed. The VENTANA PD-L1 (SP263) assay was used, and positive PD-L1 expression was defined as staining in >= 1% of tumor cells. Results Positive PD-L1 expression was observed in 181 (67.0%) patients, and 74 (27.4%) patients had brain metastasis at diagnosis. Synchronous brain metastases were more frequently observed in PD-L1-positive compared with PD-L1-negative patients (31.5% vs. 19.1%, p = 0.045). Multiple logistic regression analysis identified positive PD-L1 expression (odds ratio [OR]: 2.24, p = 0.012) as an independent factor associated with synchronous brain metastasis, along with the histological subtype of nonsquamous cell carcinoma (OR: 2.84, p = 0.003). However, the incidence of central nervous system (CNS) progression was not associated with PD-L1 positivity, with a two-year cumulative CNS progression rate of 26.3% and 28.4% in PD-L1-positive and PD-L1-negative patients, respectively (log rank p = 0.944). Furthermore, positive PD-L1 expression did not affect CNS progression or overall survival in patients with synchronous brain metastasis (long rank p = 0.513 and 0.592, respectively). Conclusions Initial brain metastases are common in NSCLC patients with positive PD-L1 expression. Further studies are necessary to understand the relationship between early brain metastasis and cancer immunity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | EGFR MUTATION | - |
dc.subject | IHC ASSAY | - |
dc.subject | IMMUNOHISTOCHEMISTRY | - |
dc.subject | NSCLC | - |
dc.subject | IMMUNOTHERAPY | - |
dc.title | Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Dae S. | - |
dc.contributor.affiliatedAuthor | Kang, Eun J. | - |
dc.identifier.doi | 10.1111/1759-7714.14006 | - |
dc.identifier.scopusid | 2-s2.0-85107734102 | - |
dc.identifier.wosid | 000661026100001 | - |
dc.identifier.bibliographicCitation | THORACIC CANCER, v.12, no.15, pp.2143 - 2150 | - |
dc.relation.isPartOf | THORACIC CANCER | - |
dc.citation.title | THORACIC CANCER | - |
dc.citation.volume | 12 | - |
dc.citation.number | 15 | - |
dc.citation.startPage | 2143 | - |
dc.citation.endPage | 2150 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | EGFR MUTATION | - |
dc.subject.keywordPlus | IHC ASSAY | - |
dc.subject.keywordPlus | IMMUNOHISTOCHEMISTRY | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | NSCLC | - |
dc.subject.keywordAuthor | PD-L1 | - |
dc.subject.keywordAuthor | brain metastasis | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | screening | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.